EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 18 / No 2 (May 2011) Parasite, 18 2 (2011) 115-119 References
Open Access
Review
Issue
Parasite
Volume 18, Number 2, May 2011
Page(s) 115 - 119
DOI https://doi.org/10.1051/parasite/2011182115
Published online 15 May 2011
  1. Berman J.D. & Lee L.S. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. American Journal of Tropical Medicine and Hygiene, 1983, 32, 753–759. [Google Scholar]
  2. Beveridge E., Goodwin L.G. & Walls L.P. A new series of leishmanicides. Nature, 1958, 182, 316–317. [CrossRef] [Google Scholar]
  3. Bories C., Cojean S., Huteau F. & Loiseau P.M. Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 164–167. [CrossRef] [Google Scholar]
  4. Coïmbra E.S., Libong D., Cojean S., Saint-Pierre-Chazalet M., Solgadi A., Le Moyec L., Duenas-Romero A.M., Chaminade P. & Loiseau P.M. Mechanism of interaction of sitamaquine with Leishmania donovani. The Journal of Antimicrobial Chemotherapy, 2010, 65, 2548–2555. [CrossRef] [PubMed] [Google Scholar]
  5. Desjeux P. Leishmaniasis: current situation and new perspectives. Comparative Immunology, Microbiology and Infectious Diseases, 2004, 27, 305–318. [CrossRef] [PubMed] [Google Scholar]
  6. Dietze R., Carvalho S.F.G., Valli L.C., Berman J., Brewer T., Milhous W., Sanchez J., Schuster B. & Grogl M. Phase II trial of WR6026, an orally administrated 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. American Journal of Tropical Medicine and Hygiene, 2001, 65, 685–689. [Google Scholar]
  7. Dueñas-Romero A.M., Loiseau P.M. & Saint-Pierre-Chazalet M. Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochimica et Biophysica Acta, 2007, 1768, 246–252. [CrossRef] [PubMed] [Google Scholar]
  8. Elderfield R.C., Mertel H.E., Mitch R.T., Wempen I.M. & Werble E.J.. Synthesis of primaquine and certain of its analogs. Journal of the American Chemical Society, 1955, 77, 4816–4819. [CrossRef] [Google Scholar]
  9. Garnier T., Brown M.B., Lawrence M.J. & Croft S.L. In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis. Journal of Pharmacy and Pharmacology, 2006, 58, 1043–1054. [CrossRef] [Google Scholar]
  10. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A. & Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine, 1999, 341, 1795–800. [CrossRef] [Google Scholar]
  11. Jha T.K., Sundar S., Thakur C.P., Felton J.M., Sabin A.J. & Horton J. A phase II dose-ranging study of sitamaquine for treatment of visceral leishmaniasis in India. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1005–1011. [Google Scholar]
  12. Kinnamon K.E., Steck E.A., Loizeaux P.S., Hanson W.L., Chapman W.L. Jr. & Waits V.B. The antileishmanial activity of lepidines. American Journal of Tropical Medicine and Hygiene,, 1978, 27, 751–757. [Google Scholar]
  13. Langreth S.G., Berman J.D., Riordan G.P. & Lee L.S. Finestructure alterations in Leishmania tropica within macrophages exposed to antileishmanial drugs in vitro. Journal of Protozoology, 1983, 30, 555–561. [Google Scholar]
  14. López-Martín C., Pérez-Victoria J.M., Carvalho L., Castanys S. & Gamarro F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrobial Agents and Chemotherapy, 2008, 52, 4030–4036. [CrossRef] [PubMed] [Google Scholar]
  15. Muschiol C., Berger M.R., Schuler B., Scherf H.R., Garzon F.T., Zeller W.J., Unger C., Eibl H.J. & Schmähl D. Alkyl phosphocholines: toxicity and anticancer properties. Lipids, 1987, 22, 930–934. [CrossRef] [PubMed] [Google Scholar]
  16. Sherwood J.A., Gachihi G.S., Muigai R.K., Skillman D.R., Mugo M., Rashid J.R., Wasunna K.M., Were J.B., Kasili S.K. & Mbugua J.M. et al. Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clinical Infectious Diseases, 1994, 19, 1034–1039. [CrossRef] [Google Scholar]
  17. Sindermann H. & Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100(Suppl 1), S17–S20. [CrossRef] [PubMed] [Google Scholar]
  18. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., Luz M., Gutierrez P., Arboleda M., Berman J.D., Junge K., Engel J. & Sindermann H. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases, 2004, 38, 1266–1272. [CrossRef] [Google Scholar]
  19. Soto J. & Berman J. Treatment of New World cutaneous leishmaniasis with miltefosine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100(Suppl 1), S34–S40. [CrossRef] [PubMed] [Google Scholar]
  20. Soto J. & Toledo J.T. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infectious Diseases, 2007, 7, 7. [CrossRef] [Google Scholar]
  21. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A. & Berman J. Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine, 2002, 347, 1739–1746. [CrossRef] [Google Scholar]
  22. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., Olliaro P. & Murray H.W. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clinical Infectious Diseases, 2008, 47, 1000–1006. [CrossRef] [Google Scholar]
  23. Theoharides A.D., Chung H., Velazquez H. Metabolism of a potential 8-aminoquinoline antileishmanial drug in rat liver microsomes. Biochemical Pharmacology, 1985, 34, 181–188. [CrossRef] [PubMed] [Google Scholar]
  24. Theoharides A.D., Kim M.M., Ashmore R.W. & Shipley L.A. Identification and quantification of human urinary metabolites of a candidate 8-aminoquinoline antileishmanial drug WR-6026. Proceedings of American Society of Experimental Biology, 1987, 46, 865. [Google Scholar]
  25. Vercesi A. & Docampo R. Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ. Biochemical Journal, 1992, 284, 463–467. [Google Scholar]
  26. Vercesi A., Rodrigues C., Castisti R. & Docampo R. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Letters, 2000, 473, 203–206. [CrossRef] [PubMed] [Google Scholar]
  27. Wasunna M.K., Rhashid J.R., Mbui J., Kirigi G., Kinoti D., Lodenyo H., Felton J.M., Sabin A.J. & Horton J. A phase II dose-increasing study of sitamaquine for treatment of visceral leishmaniasis in Kenya. American Journal of Tropical Medicine and Hygiene, 2005, 73, 871–876. [Google Scholar]
  28. World Health Organization. Leishmaniasis Disease Burden. Available from: http://www.who.int/leishmaniasis, 2010. [Google Scholar]
  29. Yeates C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Current Opinion in Investigational Drugs, 2002, 3, 1446–1452. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.